At the end of September 2013, the EMCDDA and Europol examined the available information on a new psychoactive substance 4-iodo-2,5-dimethoxy-N-(2- methoxybenzyl)phenethylamine, commonly known by the abbreviation ‘25I-NBOMe’, through

The EMCDDA–Europol Joint Report on new psychoactive substance AH-7921 (3,4-dichloro-N-[[1 (dimethylamino)cyclohexyl]methyl]benzamide), submitted in December 2013 to the Council of the EU, the European Commission and